Marshall Wace’s Ovid Therapeutics OVID Stock Holding History

Marshall Wace’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.04M	Sell	917,733 -353,754	-28%	-$632K	﹤0.01%	1776
2025 Q4	$2.07M	Buy	1,271,487 +487,834	+62%	+$751K	﹤0.01%	1563
2025 Q3	$1.02M	Buy	783,653 +618,932	+376%	+$536K	﹤0.01%	1934
2025 Q2	$54.4K	Buy	+164,721	New	+$49.6K	﹤0.01%	2595
2023 Q3	–	Sell	-30,017	Closed	-$98.5K	–	2550
2023 Q2	$98.5K	Buy	+30,017	New	+$102K	﹤0.01%	2325
2019 Q4	–	Sell	-18,060	Closed	-$59K	–	1971
2019 Q3	$59K	Buy	+18,060	New	+$41K	﹤0.01%	1471

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Marshall Wace's OVID Position: Q1 2026 in Review

Marshall Wace reduced its Ovid Therapeutics (OVID) stake by 28% in Q1 2026, selling an estimated $632K and leaving 917,733 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1776.

Marshall Wace first reported a position in OVID in Q3 2019 and has held it in 6 quarters since. The position peaked at $2.07M in Q4 2025. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

Marshall Wace held 917,733 shares of Ovid Therapeutics worth $2.04M as of Q1 2026.
Marshall Wace sold 353,754 Ovid Therapeutics shares in Q1 2026, an estimated $632K.
Ovid Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #1776 holding.
Marshall Wace first reported a position in Ovid Therapeutics in Q3 2019 and has held it in 6 quarters since.
Marshall Wace's Ovid Therapeutics position peaked at $2.07M in Q4 2025.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.